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OUTER SPACE TO INNER SPACE:
THE STORY OF THE TRANSFER OF
NASA EXCIMER LASER TECHNOLOGY
TO MEDICAL ANGIOPLASTY PROJECTS
James B. Laudenslager, Ph.D. 
Advanced Interventional Systems, Inc.
The transfer of the NASA/JPL technology started with a phone call from three 
physicians at Cedars-Sinai Medical Center (CSMC) in Los Angeles in the fall of 1983. 
The three physicians a surgeon, Dr. Warren Grundfest and two cardiologists, Drs. Frank 
Litvack and James Forrester called me in a serendipitous manner. They were calling 
local institutions to inquire about the availability of excimer laser technology to 
continue experimental studies they had started at CSMC and then continued with 
Argonne National Laboratories in Illinois. They were looking for a site in the area to 
continue their experiments on excimer laser ultraviolet radiation to ablate coronary 
blockages in the heart. CSMC was funded to do research by the NIH and later through 
private donations from hospital support groups. After discussing their ideas, I 
suggested they visit me at NASA's Jet Propulsion Laboratory (JPL). I immediately 
notified our biomedical program manager at JPL, Dr. Ed Beckenbach, to inform him of 
the meeting. At the meeting the physicians went over their current results and 
presented their proposed plan for collaboration. Since my group had pioneered the 
early development of excimer lasers and had several home-built as well as commercial 
excimer lasers, Dr. Beckenbach thought that this could be an ideal collaboration. Dr. 
Beckenbach went back to NASA Headquarters and discussed the proposed 
collaboration. He then notified us that, if we wrote a short proposal, we could obtain 
funding from the NASA Technology Utilization Office. The proposal was submitted 
and Dr. Beckenbach provided a discretionary charge number to begin collaboration 
until the proposal was formally approved and funds sent to JPL. Thus began a two and 
one half year collaboration between NASA, JPL, CSMC, and the NIH to study laser 
tissue interactions to define a suitable laser angioplasty system.
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Initial work was to reproduce the early CSMC experiments of excimer laser 
radiation on tissue both free beam as well as through fiber optics. Since excimer laser 
technology was relatively new and not user friendly, we studied various other laser 
types in the ultraviolet as well as other wavelengths. But again and again whether the 
laser was pulsed or had wavelengths with better ability to transmit through readily 
available fiber optics, the use of the JPL magnetically switched 308nm pulsed excimer 
laser provided superior results in ablating most coronary plaques. Our NASA patented 
magnetic switch technology, originally developed to increase reliability for future space 
applications of lasers, proved to be a key technology in allowing us to design the longer 
pulse duration necessary to facilitate fiber transmission to make the delivery of this 
wavelength practical for medical applications.
Dr. Beckenbach reported on the laser-tissue ablation results from this project to 
the NIH and CSMC had a press release on these laser-tissue results in the Tuesday 
science section of the New York Times. The news story of the dramatic difference for 
this laser technology as applied to the problem of coronary disease, the leading cause of 
death in the United States, had immediate response from many unique sources. Several 
news media sources such as Good Morning America, Nightline, Forbes magazine, and 
the White House generated follow-up stories. This forced the project into the public eye 
with the often asked question of when will this technology be ready for humans. This 
question then led to the next stage of this project,
The sudden press coverage gave rise to several inquires from venture capitalists 
to become involved with the project. However, after several meetings it was clear that 
they were not interested in pursuing high risk technology but just the concept to make 
money on what was then a high glamour project. The research group of physicians and 
scientists, however, viewed the success of this project to be based more on further 
technical and medical development and we believed that easy solutions would not be 
successful for laser angioplasty. Therefore, we politely rejected their offers and decided 
to carry the development to humans through continued NASA and the NIH funding.
The next stage of research was to use a long-pulse width magnetic switched laser 
with fiber optic delivery in an animal model which had to be carried out at the hospital. 
CSMC raised private money and sent it to JPL to build a research laser for the hospital 
under contract. This project was co-funded by NASA Technology Utilization money
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and NASA OAST funding for basic laser R&D for future remote sensing with excimer 
lasers. However, upon return from a summer vacation, I was informed I had lost my 
regular NASA laser R&D funding and the money from CSMC that was provided for 
JPL was sent to NASA Headquarters and was subsequently impounded with the next 
fiscal year money since Congress had not yet passed the new budget. Upon receiving 
this news, I immediately began a two fold effort to retain employment: first I tried to 
restore my NASA funding and 2) I began, in a parallel effort, seeking a means to 
continue the medical laser project outside of NASA. However, these events severely 
impacted the progress of the CSMC laser project to begin testing in animals, the next 
step before human trials.
The technology transfer effort consisted of presentations to venture capital firms, 
the generation of a business plan and a proposal to NASA for an exclusive license to the 
laser technology which Dr. Thomas Pacala and I had patented during our NASA 
research. Dr. Pacala and I were granted by NASA an exclusive license on one issued 
patent and granted options for an exclusive licenses for two pending patents with the 
ability to delay payment of any fees for a two year period to raise money for a business. 
Juggling the NASA funding from two separate NASA agencies and the CSMC contract 
became a full time effort leaving little time to work on the actual engineering 
development. Therefore, after several stops and starts, it became apparent that this 
project had to be moved to the private sector. With funding of $250,000 from a private 
investor, Ray Williams, I left JPL and co-founded Advanced Interventional Systems 
(LAIS) in the fall of 1986 and attempted to raise sufficient venture funds to carry the 
project to human clinical trials. The NASA/JPL laser was delivered to CSMC and LAIS 
after receiving four million dollars on December 31,1986, converted this laser into a 
package suitable to begin human trials.
The next step was to obtain PDA approval to begin clinical trials, to develop a 
commercial medical laser system and to develop suitable coronary catheters. This 
project required subsequent rounds of financing to complete these tasks. Finally in 
1991, we had enough data to submit an application to the PDA for product approval 
and commercialization. After a lengthy review process, the excimer laser angioplasty 
system was fully approved on January 31,1992, right after a successful public offering 
for LAIS to raise additional money to begin commercialization of the product.
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The results of this project have been very encouraging as we have been able to 
treat, to date, over 5,000 difficult coronary cases with success rates of 90% . A good 
fraction of these cases had no other option or would have needed expensive and 
traumatic by-pass surgery. The laser technology developed under the NASA program 
was one of the key technologies that allowed us to produce these successful results and 
to become the first company to receive PDA approval for a laser coronary angioplasty 
system where many other companies which went before us had failed. I believe one of 
our company's key advantages was the access to the NASA technology and the 
technical discipline instilled in us by working at NASA to do the job right.
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